J&L Pharma SRL
J&L Pharma reported total assets of 664,453 € at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026).
The score of J&L Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +32 % Total assets 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
J&L Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 38,364 € | ||||
| Equity | 385,889 € | ||||
| Cash | 3,688 € | ||||
| EBITDA | 54,208 € | ||||
| Total assets | 664,453 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jul 2025
- Year ended 31 Dec 2023filed on 12 Jul 2024
- Year ended 31 Dec 2022filed on 02 Aug 2023
- Year ended 31 Dec 2021filed on 31 Dec 2022
J&L Pharma's financial analysis
- Solvency58.1%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of J&L Pharma
J&L Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0849.895.390
- VAT number
- BE0849895390
- Peppol
- Registered · 0208:0849895390 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Oct 2012
- Registered office
- 2018 Antwerp
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
J&L Pharma (SRL) has been based in Antwerp since 2012, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 38,364 € and equity of 385,889 €; its revenue is not published. Its solvency stands at 58.1%, above the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to J&L Pharma
Companies in the same business, of comparable size and area, outside its group.
- T-Oline Business and other management consultancy activities Ferrières · balance sheet 987,312 €
- Mathis Pharma Business and other management consultancy activities Bruges · balance sheet €1.06m
- North Flow Retail sale of pharmaceutical products Antwerp · balance sheet 303,640 €
- Delvaux Holding Business and other management consultancy activities Herstal · balance sheet €1.10m
- Maxkorp Business and other management consultancy activities Ghent · balance sheet 752,596 €
- Teirlinck Retail sale of pharmaceutical products Londerzeel · balance sheet 694,347 €
- Pharmacie Overlo Retail sale of pharmaceutical products Silly · balance sheet 754,243 €
- KG Farma Retail sale of pharmaceutical products Leuven · balance sheet 622,811 €
Frequently asked questions about J&L Pharma
What is the revenue of J&L Pharma?
J&L Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of J&L Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0849895390 for J&L Pharma, if the company is VAT-registered. Its company number (CBE) is 0849.895.390.
Where is the registered office of J&L Pharma?
According to the CBE register, the registered office of J&L Pharma is in 2018 Antwerp.
What is the equity of J&L Pharma?
At the close of the 2025 financial year, the equity of J&L Pharma amounts to 385,889 €, a solvency of 58.1% of total assets.
Who manages J&L Pharma?
The register lists 1 active mandates at J&L Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of J&L Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →